Vertex gives update on CF triple combos

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) said it expects to submit an NDA by mid-2019 for a triple combination therapy to treat cystic fibrosis. The company is evaluating two different triple combinations --

Read the full 318 word article

User Sign In